Deveci S, Palese M, Parker M, Guhring P, Mulhall JP
Those with insulin-dependent or advanced diabetes may need more frequent monitoring and medication adjustments to prevent metabolic decompensation
Fifth, although adverse events and discontinuation rates were extracted, these outcomes were not formally analyzed because of substantial heterogeneity in reporting across trials, including differences in definitions, timepoints, and outcome structure (event-based vs patient-based)
The sections were then incubated with fluorescence-conjugated secondary antibodies (Alexa Fluor Cy3 and Alexa Fluor 488, 1:500, Beyotime, China)
The right protocol depends on the patients health history, symptoms, goals, labs, and medical candidacy